

CLAIMS:

1. A novel Fas ligand derivative which has protease resistance.
2. A novel Fas ligand derivative having an amino acid sequence of natural human Fas ligand wherein 129th amino acid - 130th amino acid residues from N terminal are deleted or substituted, and at least one amino acid residue of 111th amino acid - 128th amino acid residues or 131st amino acid - 133rd amino acid residues from N terminal is deleted or substituted.
3. A novel Fas ligand derivative having an amino acid sequence of natural human Fas ligand wherein 8th amino acid - 69th amino acid residues from N terminal are deleted, 129th amino acid - 130th amino acid residues from N terminal are deleted or substituted, and at least one amino acid residue of 111th amino acid - 128th amino acid residues or 131st amino acid - 133rd amino acid residues from N terminal is deleted or substituted.
4. A novel Fas ligand derivative including the amino acid sequence described in SEQ ID NO. 1 or 2.

002120 04080500

crit
C6
5. A DNA coding for the novel Fas ligand derivative of any one of claims 1 to 4.

6. An apoptosis regulator including a soluble Fas ligand.

7. A method of preventing or treating a disease wherein Fas ligand-induced apoptosis is involved, wherein the Fas ligand derivative of claims 1, 2, 3 or 4 or the apoptosis regulator of claim 6 is administered.

add C7
Add E4